Publication – Metabolomic Characterization Of Very Early Hepatocellular Carcinoma In Cirrhotic Patients Submitted For Liver Transplantation
![Cerba US Expansion Tour VF.00_04_27_19.Still010](https://cerbaresearch.com/app/uploads/2022/07/Cerba-US-Expansion-Tour-VF.00_04_27_19.Still010.jpg)
Reach out to our experts and discover how we can help you advance your clinical trial
Contact UsReach out to our experts and discover how we can help you advance your clinical trial
Contact UsReach out to our experts and discover how we can help advance your research
Contact UsIn light of the global COVID-19 (SARS-Cov-2) pandemic, the search for a treatment or vaccine has become urgent and critical. Cerba Research, together with all its partners, is widely using COVID-19 diagnostic tests to detect the virus in patients. In addition, we are assisting in making testing available in clinical trials globally.
Please, feel free to reach out to us if our COVID-19 capabilities and overall understanding of coronavirus pathogenesis can help advance the development of your treatment.
Reach out to our experts and discover how we can help advance your research
Contact UsCerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!
Reach out to our experts and discover how we can help advance your research
Contact UsWith Cerba’s network spanning five continents, team up with our experienced scientists to generate early insights and direct the course of your complex trial.
Our locations consist of cutting-edge laboratories that provide a full portfolio of specialty laboratory testing, anchored by seven centers in the Americas, Europe, Africa, and Asia-Pacific regions. With consistent, high-quality data and a road map to the patients you need, we empower you to develop personalized medicines and diagnostic solutions that will change lives worldwide.
Discover our Australia capabilities
Reach out to our experts and discover how we can help you advance your research
Contact UsReach out to our experts and discover how we can help advance your research
Contact UsLearn how Cerba Research and Fulgent are enhancing genomic data in clinical trials for better patient outcomes across all phases through their NGS services. In this presentation, you’ll learn how we’re accelerating precision medicine with next generation biomarker discovery through our partnership and specific expertise in oncology, rare disease, CNS, metabolic, and infectious diseases.
Our Histoprofile®- T-reg light panel is ready for use in your clinical trials
Accurate characterization of the tumor micro-environment when tissue sample access is limited can be an important challenge in the field of immuno-oncology. The balance and tumor infiltration of T cell subpopulations are of particular interest and its importance has been repeatedly demonstrated in the literature. T cells are important immune effector cells and are therefore preferred targets for immuno-modulation.
Conventional T cells can be broadly classified as helper (Th), cytotoxic (Tcyto), memory or regulatory (Treg) cells. Tcyto cells ensure optimal immune responses against invading microbes and tumor antigens. Under homeostatic conditions, Tregs promote peripheral tolerance. However, within tumors, Tregs can supress Tcyto cell functions. The multiplex protocol, Histoprofile®- T-reg light panel, developed at Cerba Research on the Discovery ULTRA (Ventana) platform is designed to stain specific sub-populations of T cells on a single slide, avoiding the need of serial sections from precious patient’s FFPE samples in clinical trials while still providing an indepth analysis of the tumor microenvironment.
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.
Reach out to our experts and discover how we can help advance your clinical trial
Contact UsHematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.
Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.
At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.
Reach out to our experts and discover how we can help you advance your research
Contact UsHISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).
Reach out to our experts and discover how we can help you advance your research
Contact Us